Romaco Group Sells FrymaKorum?a to ProXES
The Romaco Group is selling its stake in FrymaKoruma AG (Rheinfelden, Switzerland) and FrymaKoruma GmbH (Neuenburg) to a new umbrella corporation within the Deutsche Beteiligungs AG (DBAG Frankfurt).
“During more than 10 years in affiliation with the Romaco Group, FrymaKoruma developed very well. We are pleased to offer a further growth spurt to the company in a group that specialises in process technology. Through this transaction, Romaco will focus even more on the development of its competences, especially in the pharmaceuticals market,” says Paulo Alexandre, CEO of the Romaco Group.
The companies Stephan Machinery (Hameln) and FrymaKoruma will co-operate under the new umbrella corporation ProXES. Both companies have strong brands in the area of food, pharmaceutical and health care technology and they also see an excellent complement to their previous applications and their market presence in their common future. A clear focus on process technology will ensure a stronger market position under the common umbrella corporation. Therefore, the DBAG portfolio company ProXES is acquiring the entire stake in FrymaKoruma (AG and GmbH) from the Romaco Group.
“Within the Romaco Group, we were already able to make use of significant incentives for the development of FrymaKoruma”, says Thomas Merle, director of FrymaKoruma, a little wistful about leaving the group. “We are very pleased that we can now realise previously unknown possibilities within our core business with the help of ProXES and its clear focus on process technology.”
Olaf Pehmöller, CEO of Stephan Machinery, is also happy about their new partner. “FrymaKoruma and Stephan Machinery complement each other to the benefit of both companies. For our customers, we are developing a process technology group consistent with an enterprise size which can offer more attractive proposals in better quality”, says Pehmöller, who will also act as CEO for the ProXES Group.
ProXES stands for ‘Processing and eXpert Engineering Services’, whereby the new name is at the same time a promise to our customers and thus a responsibility for the new partners. The principal shareholder is also satisfied with this focus: “With FrymaKoruma and Stephan Machinery, we have two companies which are active on the market with strong brands and an excellent reputation. The combining of the respective excellences is the logical consequence of our growth strategy which we will now implement in a focussed way”, says Dr Rolf Scheffels, member of the board of the Deutsche Beteiligungs AG.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance